{"prompt": "['2017N330177_04', 'CONFIDENTIAL', '205678', 'IMWG', 'International Myeloma Working Group', 'INR', 'International normalization ratio', 'IP', 'Investigational product', 'IRB', 'Institutional review board', 'IRC', 'Independent Review Committee', 'IRR', 'Infusion related reaction', 'IRT', 'Interactive Response Technology', 'IUD', 'Intra-uterine device', 'IUS', 'Intrauterine hormone-releasing system', 'IV', 'Intravenous', 'LC', 'Light chain', 'LDH', 'Lactate dehydrogenase', 'LLN', 'Lower limit of normal (range)', 'LSFV', \"Last subject's first visit\", 'LVEF', 'Left ventricular ejection fraction', 'mAb', 'Monoclonal antibody', 'MDRD', 'Modified diet in renal disease', 'MM', 'Multiple myeloma', 'MMAF', 'Monomethyl auristatin-F', 'MOA', 'Mechanism of Action', 'MR', 'Minimal Response.', 'MRD', 'Minimal residual disease', 'MRI', 'Magnetic resonance imaging', 'MSDS', 'Material Safety Data Sheet', 'NCI', 'National Cancer Institute', 'NE', 'Not evaluable', 'NEI-VFQ-25', 'National Eye Institute 25-Item Visual Function Questionnaire', 'NGS', 'Next Generation Sequencing', 'NYHA', 'New York Heart Association', 'ORR', 'Overall Response Rate', 'OS', 'Overall survival', 'OSDI', 'Ocular Surface Disease Index', 'PCR', 'Polymerase chain reaction', 'PD', 'Progressive disease', 'PET', 'Positron Emission Tomography', 'PFS', 'Progression Free Survival', 'PI', 'Principal Investigator', 'PK', 'Pharmacokinetics', 'PR', 'Partial response', 'PRO', 'Patient reported outcome', 'PRO-CTCAE', 'Patient-Reported Outcome Version of the Common Term Criteria for', 'Adverse Events', 'PTS', 'Platform Technologies and Science', 'Q21D', 'Once every 21 days', 'Q3W', 'Once every 3 weeks', 'QID', 'Four times a day', '107']['2017N330177_04', 'CONFIDENTIAL', '205678', 'QLQ-C30', 'Quality of Life Questionnaire 30-item Core module', 'QLQ-MY20', 'Quality of Life Questionnaire 20-item Multiple Myeloma module', 'QTc', 'Corrected QT interval (ECG)', 'QTcF', 'Corrected QT interval Fridericia', 'RAMOS', 'Registration and Medication Ordering System', 'RAP', 'Reporting and Analysis Plan', 'RBC', 'Red blood cell', 'RNA', 'Ribonucleic acid', 'RP2D', 'Recommended Phase II Dose', 'RRMM', 'Relapsed / refractory multiple myeloma', 'SAE', 'Serious adverse event', 'sCR', 'Stringent Complete Response', 'SCT', 'Stem cell transplant', 'SD', 'Stable disease', 'SOA', 'Schedule of activities', 'SOI', 'Start of infusion', 'SOP', 'Standard operating procedure', 'SPD', 'Sum of the products of the maximal perpendicular diameters of', 'measured lesions', 'SPEP', 'Serum Protein Electrophoresis', 'SRM', 'Study Reference Manual', 'SUSAR', 'Suspected Unexpected Serious Adverse Reaction', 'SUV', 'Standardized uptake value', 't\u00b9/2', 'Terminal phase half-life', 'TCR', 'T-Cell receptor', 'TLS', 'Tumor Lysis syndrome', 'tmax', 'Time of maximum observed concentration', 'TNF', 'Tumor necrosis factor', 'TTP', 'Time to progression', 'TTR', 'Time to (best) Response', 'TTR', 'Time to response', 'UK', 'United Kingdom', 'ULN', 'Upper limit of normal', 'UPEP', 'Urine protein electrophoresis', 'US', 'United States', 'USP', 'United States Pharmacopeia', 'V', 'Volume of distribution', 'VGPR', 'Very good partial response', 'WBC', 'White blood cell', 'WFI', 'Sterile water for injection', 'WOCBP', 'Woman of Childbearing Potential', '\u00df-HCG', 'Beta human chorionic gonadotropin', '108']\n\n###\n\n", "completion": "END"}